DGAP-News: Raptor Pharmaceutical Corp. Announces the Appointment of Henk Doude van Troostwijk as General Manager of European Commercial Operations

Raptor Pharmaceutical Corp.

28.03.2012 12:30
—————————————————————————

Raptor Establishes European Headquarters in the Netherlands

NOVATO, Calif., 2012-03-28 12:30 CEST (GLOBE NEWSWIRE) —
Raptor Pharmaceutical Corp. (–Raptor– or the –Company–) (Nasdaq:RPTP),
announced the appointment of Henk Doude van Troostwijk as its General Manager
of European Commercial Operations, effective April 15, 2012. Mr. Doude van
Troostwijk will be responsible for building and managing Raptor–s commercial
operations in Europe initially focusing on the potential launch and subsequent
marketing of RP103 for nephropathic cystinosis in anticipation of the European
Medicines Agency–s approval of Raptor–s marketing application. Raptor is
planning to base its European headquarters in Leiden, the Netherlands.

Patrick Reichenberger, Vice President of Commercial Operations stated, –We are
very excited to have Henk join our team to lead the commercial operations in
Europe. His expertise in gaining market access, working with orphan products
and leading commercial teams will be critical as we prepare for the potential
launch of RP103 in Europe.–

Mr. Doude van Troostwijk most recently served within Genzyme, a Sanofi company,
as Business Unit Director, Oncology, for Haematology and Transplantation in
Northern Europe. In that position, his responsibilities included management of
the reimbursement process, implementation of marketing strategies and business
plans, recruitment and training of new colleagues, public relations, outreach
to key opinion leaders and development of medical communications. Before that,
Mr. Doude van Troostwijk held the title of Country Manager for Bioenvision,
where he was responsible for building infrastructure and launching Evoltra, an
orphan drug for leukemia, in the Benelux region. Mr. Doude van Troostwijk began
his career at Nycomed before taking management positions in sales and marketing
at Merck Sharp&Dohme and Bristol Myers Squibb.

About Nephropathic Cystinosis

Nephropathic cystinosis, an orphan disease, is estimated to effect a population
of 2,000 patients worldwide, including 500 patients in the U.S. and 800
patients in Europe. Cystinosis patients have inherited a defective cystine
transporter gene which results in body-wide cellular toxicity resulting from
the abnormal buildup of the amino acid cystine in the lysosomes. Cystinosis is
usually diagnosed in the first year of life and requires lifelong therapy.
Cystine crystals accumulate in various tissues and organs, including the
kidneys, brain, liver, thyroid, pancreas, muscles and eyes. Left untreated, the
disease is fatal by the first decade of life. RP103 reduces cellular toxicity
by continuously removing cystine from the lysosome.

About Cysteamine and RP103

RP103 is Raptor–s proprietary delayed and extended release oral medication to
treat the underlying metabolic cause of cystinosis. RP103 is an enteric coated,
microbead formulation of cysteamine bitartrate that has been formulated to be
sprinkled onto food for administration to patients too young to take oral
capsules. Raptor has been granted orphan product designation for RP103 by the
EMA and FDA.

In December 2007, Raptor obtained an exclusive, worldwide license from the
University of California, San Diego forthe development of RP103 for
nephropathic cystinosis and for cysteamine for other potential indications
including Huntington–s Disease currently in a Phase 2/3 clinical trial in
France and non-alcoholic steatohepatitis (–NASH–) currently in a Phase 2b
clinical trial in the U.S.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (–Raptor–) seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis (–NASH–), Huntington–s Disease (–HD–), aldehyde dehydrogenase
deficiency (–ALDH2–), and thrombotic disorder.

Raptor–s preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance, including, but not limited to the following statements: that Mr.
Doude van Troostwijk will start employment on April 15, 2012; that Mr. Doude
van Troostwijk will be able to build and manage Raptor–s commercial operations
in Europe; that Raptor will gain marketing approval of RP103 in the U.S. or in
Europe; that Raptor will be able to launch and subsequently market RP103 for
nephropathic cystinosis in Europe; that Raptor will base its European
headquarters in the Leiden, the Netherlands; and that Raptor will be able to
successfully develop any of its other product candidates. These statements are
only predictions and involve known and unknown risks, uncertainties and other
factors, which may cause the Company–s actual results to be materially
different from these forward-looking statements. Factors which may
significantly change or prevent the Company–s forward looking statements from
fruition include: that Raptor may be unsuccessful in developing any products or
acquiring products; that Raptor–s technology may not be validated as it
progresses further and its methods may not be accepted by the scientific
community; that Raptor is unable to retain or attract key employees whose
knowledge is essential to the development of its products; that unforeseen
scientific difficulties develop with the Company–s process; that Raptor–s
patents are not sufficient to protect essential aspects of its technology; that
competitors may invent better technology; that Raptor–s products may not work
as well as hoped or worse, that the Company–s products may harm recipients; and
that Raptor may not be able to raise sufficient funds for development or
working capital. As well, Raptor–s products may never develop into useful
products and even if they do, they may not be approved for sale to the public.
Raptor cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater detail in the
Company–s filings from time to time with the Securities and Exchange Commission
(the –SEC–), which Raptor strongly urges you to read and consider, including:
Raptor–s annual report on Form 10-K and Amendment No. 1 to its Annual Report on
Form 10-K/A filed with the SEC on November 14, 2011 and December 19, 2011,
respectively; and Raptor–s quarterly report on Form 10-Q filed with the SEC on
January 6, 2012, which are available free of charge on the SEC–s web site at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to Raptor or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth in Raptor–s
reports filed with the SEC. Raptor expressly disclaims any intent or obligation
to update any forward-looking statements.

CONTACT: Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com

EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX

28.03.2012 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Raptor Pharmaceutical Corp.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:

End of Announcement DGAP News-Service

—————————————————————————

  raptor-pharmaceutical-corp-announces-the-appointment-of-henk-doude-van-troostwijk-as-general-manager-of-european-commercial-operations